statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced that it expects to initiate the first...

EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year

Vivani Medical plans to start the first clinical study of the NPM-115 program in Australia in Q4 2024. The study will evaluate a 6-month GLP-1 implant for chronic weight management in obese or...

Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced the U.S. Food and Drug Administration...

EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's NDA Gains FDA Clearance For Clinical Use

Vivani Medical cleared FDA for NPM-119 trial in type 2 diabetes. LIBERATE-1 will assess safety, tolerability, & pharmacokinetics. NPM-115 & NPM-139 also in development for weight management.
read more...

Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight...

EXCLUSIVE: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use

Vivani Medical announced proof-of-concept data for a subdermal exenatide implant designed for feline obesity and diabetes, which was published in BMC Veterinary Research.
read more...

Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results

Vivani Medical to Present at TIDES Conference 2024

Vivani Medical Inc (VANI) Reports Fourth Quarter and Full Year 2023 Financial Results

Strategic Shift and Financing Round Highlight VANI's Year-End SummaryRelated Stocks: VANI...

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.

Volume	67,883.00
52-Wk High	$7.80
52-Wk Low	$0.84

VANI Vivani Medical Inc

About

Feed

News

Earnings

Fundamentals